Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas

International Journal of Cancer

Volumn 101, Issue 2, 2002, Pages 190-195

  Resnick, Murray B ^a,e   Sabo, Edmond ^a   Kondratev, Svetlana ^a   Kerner, Hedviga ^b   Spagnoli, Giulio C ^c   Yakirevich, Evgeny ^d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c Department of Surgery ^*  (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CARMEL MEDICAL CENTER   (Israel)

Author keywords

Cancer testis antigen; Carcinosarcoma; Endometrial cancer; MAGE A4; NY ESO 1; Papillary serous carcinoma

Indexed keywords

ANTIGEN MAGE A4; ANTIGEN NY ESO 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; UTERUS CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; CARCINOSARCOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROTEINS; UTERINE NEOPLASMS;

EID: 0037056217     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10585     Document Type: Article

References (44)

1. Cancer tumor antigens
2. T cell defined tumor antigens
3. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
4. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells
5. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
6. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma
7. Identification and intracellular location of MAGE-3 gene product
8. MAGE-3 immunoreactivity in formalinfixed, paraffin embedded primary and metastatic melanoma: Frequency and distribution
9. Monoclonal antibody (MAb) 57B stains tumor tissues that express gene MAGE-A4
10. Expression of the MAGE 3 product in squamous cell carcinomas of the head and neck
11. Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma
12. MAGE-1 and MAGE-3 tumor rejection antigens in human germ cell tumors
13. Expression of Mage-antigens in normal tissues and cancer
14. Expression of MAGE tumor associated antigens is inversely correlated with tumor differentiation in invasive ductal breast cancers. An immunohistochemical study
15. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
16. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28
17. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-al or ct7
18. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell-lines and clinical specimens
19. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
20. Uterine tumors with mixed epithelial and mesenchymal components
21. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features
22. Uterine papillary serous carcinoma: A study of 108 cases with an emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma
23. MAGE, BAGE and GAGE gene expression in fresh epithelial ovarian carcinomas
24. Expression of MAGE-1, MAGE-2, MAGE 3/-6 and MAGE 4a/-4b genes in ovarian tumors
25. Immunoreactivity with the Anti-MAGE antibody 57B in malignant melanoma: Frequency of expression and correlation with prognostic parameters
26. Expression of MAGE antigens in renal cell carcinoma
27. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade
28. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder
29. Expression of MAGE antigens in testicular germ cell tumors
30. MAGE, BAGE and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia
31. Expression of multiple cancer-testis antigens in gastrointestinal and breast carcinomas
32. The immunohistochemical profile of malignant mixed mullerian tumor
33. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: A clinicopathologic and immuno-histochemical study
34. Malignant mixed mullerian tumors: An immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation
35. Carcinosarcoma (malignant mixed mullerian [mesodermal] tumor) of the uterus and ovary: Correlation of clinical, pathologic and immunohistochemical features in 29 cases
36. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): A clinicopathologic study of 74 cases
37. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal
38. Epidermal growth factor receptor and cerb-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors): Clinicopathologic study of 82 cases
39. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: Comparative molecular analysis of the epithelial and mesenchymal elements
40. Carcinosarcoma of the uterus: Immunohistochemical and genetic analysis of clonality of one case
41. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: A comparative analysis of survival
42. Smooth muscle, endometrial stromal and mixed Mullerian tumors of the uterus
43. The activation of human gene MAGE-1 in tumor cells correlates with genome-wide demethylation